Becton Dickinson (BDX)
180.90
+2.63 (1.48%)
NYSE · Last Trade: Jul 17th, 11:18 PM EDT
Detailed Quote
Previous Close | 178.27 |
---|---|
Open | 178.27 |
Bid | 176.24 |
Ask | 182.45 |
Day's Range | 177.10 - 181.04 |
52 Week Range | 163.33 - 251.99 |
Volume | 3,946,282 |
Market Cap | 51.95B |
PE Ratio (TTM) | 35.06 |
EPS (TTM) | 5.2 |
Dividend & Yield | 4.160 (2.30%) |
1 Month Average Volume | 3,258,367 |
Chart
About Becton Dickinson (BDX)
Becton Dickinson is a global medical technology company that specializes in the development and manufacture of medical devices, instrument systems, and reagents. The company focuses on improving patient care and advancing healthcare delivery through its diverse product offerings, which include syringes, needles, blood collection systems, and diagnostic tools. With a strong commitment to innovation and quality, Becton Dickinson serves healthcare professionals and institutions around the world, facilitating safe and effective medical procedures and enhancing the overall health and well-being of patients. Read More
News & Press Releases
Calm Before the Storm? Wall Street Holds Its Breath Ahead of Earnings and Inflation Bombshells
Via Chartmill · July 15, 2025
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how surgical equipment & consumables - diversified stocks fared in Q1, starting with BD (NYSE:BDX).
Via StockStory · July 14, 2025
BALA CYNWYD, Pa., July 14, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
By Brodsky & Smith LLC · Via GlobeNewswire · July 14, 2025
BD to spin off its diagnostics and biosciences business in a $17.5 billion merger with Waters, targeting $345 million in synergies by 2030.
Via Benzinga · July 14, 2025
Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence.
With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.
Via StockStory · July 14, 2025
Via The Motley Fool · July 11, 2025
Wall Street has set ambitious price targets for the stocks in this article.
While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
Via StockStory · July 11, 2025
Generating cash is essential for any business, but not all cash-rich companies are great investments.
Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Via StockStory · June 30, 2025
Becton Dickinson stock (BDX): Signs point toward continued underperformance until early June 2027.
Via Benzinga · June 25, 2025
Via Benzinga · June 18, 2025

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,
and over the past six months, the industry has pulled back by 12.3%. This performance was noticeably worse than the S&P 500’s 1.9% fall.
Via StockStory · June 4, 2025
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer.
However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.
Via StockStory · May 23, 2025
Via Benzinga · May 22, 2025
Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies.
Via StockStory · May 15, 2025
Medical technology company Becton, Dickinson and Company (NYSE:BDX) missed Wall Street’s revenue expectations in Q1 CY2025 as sales rose 4.5% year on year to $5.27 billion. On the other hand, the company’s outlook for the full year was close to analysts’ estimates with revenue guided to $21.85 billion at the midpoint. Its non-GAAP profit of $3.35 per share was 2.1% above analysts’ consensus estimates.
Via StockStory · May 14, 2025
Sanofi plans $20 billion US investment by 2030 to expand R&D and manufacturing, aiming to boost medicine production and job creation across states.
Via Benzinga · May 14, 2025
Only about 50% of S&P 500 stocks trade above their 200-day average, signaling narrow breadth even as the index rallies 22% since April.
Via Benzinga · May 14, 2025
A company with profits isn’t always a great investment.
Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
Via StockStory · May 9, 2025
FDA to increase surprise inspections at foreign facilities as U.S. companies pour billions into domestic drug and device manufacturing.
Via Benzinga · May 6, 2025
Via Benzinga · May 4, 2025
Becton Dickinson receives multiple downgrades as analysts cite weakening organic growth and trimmed price targets following a Q2 update.
Via Benzinga · May 2, 2025